corcept.png
Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors
June 10, 2021 07:30 ET | Corcept Therapeutics Incorporated
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
corcept.png
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
May 06, 2021 16:10 ET | Corcept Therapeutics Incorporated
In a 178-patient, controlled, Phase 2 trial, women with platinum-resistant ovarian cancer who received relacorilant plus nab-paclitaxel experienced improved progression free survival (PFS) compared to...
Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)
May 06, 2021 16:05 ET | Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer
May 06, 2021 16:01 ET | Corcept Therapeutics Incorporated
Women with platinum resistant ovarian cancer experienced longer progression free survival with relacorilant plus nab-paclitaxel than with nab-paclitaxel aloneWomen who received a higher dose of...
corcept.png
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 29, 2021 16:05 ET | Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update...
corcept.png
Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess
March 15, 2021 07:30 ET | Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
corcept.png
Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
March 01, 2021 16:05 ET | Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
corcept.png
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
February 23, 2021 16:05 ET | Corcept Therapeutics Incorporated
2020 revenue of $353.9 million, compared to $306.5 million in 2019Fourth quarter revenue of $85.7 million, compared to $87.9 million in 20192020 GAAP net income of $106.0 million, compared to $94.2...
corcept.png
Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update
February 08, 2021 16:05 ET | Corcept Therapeutics Incorporated
Financial Highlights, 2021 Revenue Guidance and Legal Update Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019Preliminary fourth quarter revenue $85.7 million, compared to...
corcept.png
Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call
February 01, 2021 16:05 ET | Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial...